Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ranica – page 175

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ranica at a glance
2 668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 668 trials in Ranica

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Myotonic dystrophy

Not recruiting

Safety and effectiveness study of DYNE-101 in patients with Myotonic Dystrophy Type 1 (DM1)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Dyne Therapeutics Inc.

Mucopolysaccharidosis I

Not recruiting

Study on the Effectiveness and Safety of OTL-203 for Patients with Hurler Syndrome (MPS-IH) Compared to Standard Treatment with Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:Orchard Therapeutics (Europe) Limited

Splenic marginal zone lymphoma

Not recruiting

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Hepatocellular carcinoma

Not recruiting

Study on Advanced Liver Cancer: Evaluating Livmoniplimab and Budigalimab in Patients Without Prior Systemic Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hepatocellular carcinoma

Not recruiting

Study of nivolumab, relatlimab and bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol Myers Squibb International Corporation

Influenza

Not recruiting

Study of intravenous zanamivir safety and effectiveness in infants under 6 months of age with complicated influenza infection

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Zanamivir
  • Sponsor:Glaxosmithkline Research & Development Limited

Multiple sclerosis

Not recruiting

Study on the Effects of SAR443820 and Gadobutrol in Patients with Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Gadobutrol
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

  • IC-MPGN Treatment Evaluation
  • C3 Glomerulopathy Research
  • Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

  • Primary Membranous Nephropathy
  • IgA Nephropathy Interventions
  • Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

  • Disease Progression Prevention
  • Hyperkalemia Management
  • Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.